论文部分内容阅读
本文报道,用人免疫球蛋白E 五肽(HEPP)治疗过敏症的疗效及其量-效关系的研究。选12例证实为IgE 介导的变应性鼻炎患者,随机分为,HFPP 治疗组和安慰剂组。治疗组5例分别于第1、4、7、10、12和14天皮下注射HEPP2、2、10、20、100、100mg;另3例分别注射2、2、20、20、100、100mg的HEPP。对照组4例仅于皮下注射安慰剂(0.5ml 磷酸盐缓冲生理盐水)。实验前3天均停止使用抗组胺药物。
This article reports the efficacy and the dose-response relationship of human immunoglobulin E pentapeptide (HEPP) in the treatment of allergy. Twelve patients with confirmed IgE-mediated allergic rhinitis were randomized into HFPP-treated and placebo-treated patients. The treatment group, 5 cases were subcutaneously injected with HEPP2,2,10,20,100,100mg on the 1st, 4th, 7th, 10th, 12th and 14th day respectively; the other 3 cases were injected with 2,2,20,20,100,100 mg HEPP. Four patients in the control group were injected subcutaneously with placebo (0.5 ml phosphate buffered saline). Antihistamines were discontinued 3 days before the experiment.